Cancer Vaccines

Irradiated B7-1 Transduced Primary Leukemia Cells Effective as AML Vaccine

Published in Vaccine Weekly, April 29th, 1996

Irradiated primary acute myelogenous leukemia (AML) cells, transduced with the B7-1 costimulatory molecule, generate a tumor-specific immunity in a murine model.

Current chemotherapeutics are capable of inducing remission in 60 to 80 percent of AML patients. Unfortunately, long-term survival is usually only achieved in 25 to 30 percent of these patients.

Motivated by the need for new therapeutic modalities for AML, and encouraged by the recent discoveries in tumor immunology, Kyriaki Dunussi-Joannopoulos et al. tested the antitumor effects of a cancer vaccine specific against AML in a murine model ("Irradiated B7-1 Transduced Primary Acute...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1996-04-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry